RT combined with anti-PD-L1 and anlotinib (triple therapy) group significantly inhibited tumor growth compared to the radioimmunotherapy and IR plus anlotinib groups, whereas C-176 attenuated the antitumor efficacy of triple therapy (Fig. 5B, C). This evidence concerns the gene CD274 and neoplasm.